Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q3 Revenue: USD 17.63 M

LB filings
2025.11.14 13:48
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 17.63 M.

EPS: As of FY2025 Q3, the actual value is USD 0.11.

EBIT: As of FY2025 Q3, the actual value is USD -4.805 M.

Journey Medical Corporation (Journey)

  • Net Revenue: $17.6 million for the three months ended September 30, 2025, compared to $14.6 million for the same period in 2024.
  • Cost of Goods Sold: $5.8 million for the three months ended September 30, 2025, compared to $4.5 million for the same period in 2024.
  • Amortization of Acquired Intangible Assets: $1.1 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024.
  • Research and Development Expenses: $0.3 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024.
  • Selling, General and Administrative Expenses: $12.1 million for the three months ended September 30, 2025, compared to $11.4 million for the same period in 2024.
  • Stock-Based Compensation - Selling, General and Administrative: $1.9 million for the three months ended September 30, 2025, compared to $1.5 million for the same period in 2024.

Avenue Therapeutics (Avenue)

  • Research and Development Expenses: $0.2 million for the three months ended September 30, 2025, compared to $2.3 million for the same period in 2024.
  • Selling, General and Administrative Expenses: $0.5 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024.
  • Stock-Based Compensation - Selling, General and Administrative: $0.1 million for the three months ended September 30, 2025, compared to $0.2 million for the same period in 2024.

Mustang Bio, Inc. (Mustang)

  • Research and Development Expenses: - $0.3 million for the three months ended September 30, 2025, compared to $0.1 million for the same period in 2024.
  • Selling, General and Administrative Expenses: $1.0 million for the three months ended September 30, 2025, compared to $1.4 million for the same period in 2024.
  • Stock-Based Compensation - Selling, General and Administrative: $0.02 million for the three months ended September 30, 2025, compared to $0.05 million for the same period in 2024.

Fortress Biotech, Inc. (Fortress)

  • Research and Development Expenses: $0.1 million for the three months ended September 30, 2025, compared to - $0.1 million for the same period in 2024.
  • Selling, General and Administrative Expenses: $3.9 million for the three months ended September 30, 2025, compared to $5.0 million for the same period in 2024.
  • Stock-Based Compensation - Selling, General and Administrative: $1.0 million for the three months ended September 30, 2025, compared to $2.5 million for the same period in 2024.

Consolidated

  • Net Revenue: $17.6 million for the three months ended September 30, 2025, compared to $14.6 million for the same period in 2024.
  • Cost of Goods Sold: $5.8 million for the three months ended September 30, 2025, compared to $4.5 million for the same period in 2024.
  • Amortization of Acquired Intangible Assets: $1.1 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024.
  • Research and Development Expenses: $0.2 million for the three months ended September 30, 2025, compared to $9.4 million for the same period in 2024.
  • Selling, General and Administrative Expenses: $17.4 million for the three months ended September 30, 2025, compared to $22.0 million for the same period in 2024.
  • Stock-Based Compensation - Selling, General and Administrative: $3.0 million for the three months ended September 30, 2025, compared to $5.4 million for the same period in 2024.
  • Interest Income: $0.7 million for the three months ended September 30, 2025, compared to $0.6 million for the same period in 2024.
  • Interest Expense and Financing Fee: $2.7 million for the three months ended September 30, 2025, compared to $6.2 million for the same period in 2024.
  • Other Income: $17.7 million for the three months ended September 30, 2025, compared to $1.1 million for the same period in 2024.
  • Net Income (Loss) Attributable to Fortress: $5.9 million for the three months ended September 30, 2025, compared to - $12.9 million for the same period in 2024.

Future Outlook and Strategy

  • Journey Medical Corporation: Journey plans to continue expanding the payer coverage for Emrosi and other marketed products, focusing on increasing market penetration and sales.
  • Avenue Therapeutics: Avenue will focus on advancing its clinical development programs and exploring strategic partnerships to support its pipeline.
  • Mustang Bio, Inc.: Mustang will continue to streamline its operations, focusing on advancing its clinical programs and managing costs effectively.
  • Fortress Biotech, Inc.: Fortress will continue to leverage its expertise to support its subsidiaries and partner companies, exploring strategic arrangements to accelerate funding and development.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer